Eight years after Eli Lilly dumped it, an upstart biotech has nabbed teplizumab and filed a $56M IPO to back a PhIII comeback
Eight years ago, a drug called teplizumab went down in flames after it failed in a pivotal diabetes study undertaken by Eli Lilly. But yesterday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
